Top 100 PAA Share Holders as at 29th December 2022 with variations, page-4

Thanks @RAN58 and wishing you and your family a great 2023.

I think it's fair to say 2022 was a bit disappointing in terms of SP, however I believe a fair review shows we made and continue to make progress towards commercialization. My view is that the BOD could have done better in explaining the pivot away from the stated plan to run multiple trials in 2022, the only one that actually started was the Phase 1/2 MND trial. That alone is a great achievement however, and I'm looking forward to seeing some results. The canine trial is building and we now have a greater understanding of the sometimes slow recruitment and how it is necessary to sell it as a possible new market particularly interesting is the similarities in life expediency between the dogs that achieve stable disease and progressive. Keep in mind that we are tackling a particularly aggressive cancer and think about the possibilities in human cancers.

We experienced a 36% drop since Jan 3rd, but we are not orphans and in fact have done much better than most other Australian Biotech's I have included a snippet below. The full list can be seen here. https://**.st/stocks/au/pharmaceuticals-biotech/market-cap-small



So here is hoping for continued development along with a much deserved increase in dollar terms in 2023.

I think we all deserve a drink tonight